Why Regeneron Investors Shouldn't Fear Its Patent Cliff

Biotechnology giant Regeneron's (NASDAQ: REGN) eye medication EYLEA is one of the best-selling blockbuster drugs around, generating $9.4 billion sales globally in 2021. The drug is approved for a number of eye diseases and has been a mainstay for Regeneron for the past decade. Although its patents are nearing the end of their lifespan, Regeneron has a number of new treatments that will step in to replace lost revenue.

Image source: Getty Images.

EYLEA is an eye injection used to prevent vision loss in patients with age- or diabetes-related retinal disease. With over 50 million doses administered worldwide, the drug is Regeneron's top-selling product by a large margin. Even after splitting profits outside of the United States with collaborator Bayer (OTC: BAYZ.F), Regeneron still received $1.9 billion in sales in the first quarter of 2022, providing 64% of Regeneron's total revenue.

Continue reading

Source Fool.com